[Removal of a dermoid cyst of the floor of the mouth in a patient with severe hemophilia A]. / Udalenie dermoidnoi kisty dna rta u bol'nogo tyazheloi formoi gemofilii A.

The article presents a case of a surgical treatment of removing a dermoid cyst of the floor of the oral cavity in a patient with severe hemophilia A. A detailed analysis was carried out of the surgical operation, postoperative management, coagulation factor replacement therapy and accompanying therapy, as well as the features of anesthesia, which allowed a surgical intervention without any hemorrhagic and infectious complications.

[Clinical efficacy and safety of Ethoxidol in cerebrovascular diseases]. / Klinicheskaya effektivnost' i bezopasnost' Etoksidola pri tserebrovaskulyarnykh zabolevaniyakh.

OBJECTIVE: Evaluation of efficacy and clinical safety of ethylmethylhydroxypyridine malate (Ethoxidol) in cerebrovascular disease in out-patient, and in-patient setting. MATERIAL AND METHODS: In the observational study was included of the 70 patients (aged 62.84±6.54 y.o) diagnosed with unspecified cerebrovascular disease, hypertensive encephalopathy, atherosclerosis of cerebral vessels. To access neurological deficit Montreal Scale (MoCA test) was used, MFI-20 test for asthenia. Berg balancing (BBS-test), tinnitus severity score (THI), and general clinical condition score also were recorded. Quality assurance was evaluated by VAS, and EQ-VAS Scores (European life quality gr). Interventions were identical, except treated received Ethoxidol 200 mg IV once/day, or 200 mg IM once/day and 200 mg per os (400 mg/day) during 7 days, follow up by oral administration of Ethoxidol 600 mg/day (200 mg TID) for the period of 53 days. RESULTS: The results of the observational study has shown of high clinical efficacy and tolerability of the Ethoxidol therapy. Statistical significance between baseline and treatment period was recorded on the 7th and 60th day of observation (p<0.001). Stabilization of the archived condition persisted on the 60th day. Ethoxidol administration reduced asthenia cognitive dysfunction, dizziness, balance disorders, and tinnitus. CGI Score revealed reduction of the severity of patient's condition and total of clinical improvement; EQ-VAS Score showed growth of quality of life. The majority of patients were satisfied with performed therapy, attending physicians highlight Ethoxidol safety. Serious adverse events weren't recorded. CONCLUSION: Ethoxidol was considered as efficient and safe medication for in-patient and out-patient treatment of patient with cerebrovascular diseases (chronic cerebral ischemia).

[Effects of the Hydrogen Sulfide Donor GYY4137 and HSP70 Protein on the Activation of SH-SY5Y Cells by Lipopolysaccharide].

The effects of exogenous recombinant human heat shock protein Hsp70 and hydrogen sulfide donor GYY4137 on the mechanisms of endocytosis of lipopolysaccharide (LPS) by human neuroblastoma cells SH-SY5Ywas studied. Hsp70 and GYY4137 have been shown to significantly reduce LPS-induced production of inflammatory mediators by SH-SY5Y cells, including reactive oxygen species, nitric oxide, TNFα, IL-1ß, and IL-6. Both the recombinant protein Hsp70 and the hydrogen sulfide donor GYY4137 exhibited significant protective effects; however, the combined use of these agents did not lead to a cumulative effect. It has been shown that pinocytosis, as well as clathrin-, caveolin-, tubulin- and receptor-dependent endocytosis were involved in protecting the cells by both the hydrogen sulfide donor and Hsp70 from LPS-induced production of reactive oxygen species and NO.

[Silentscope - new method of diagnosis and treatment of patients with salivary stone disease. The border need to use]. / Sialoéndoskopiia - novyi metod diagnostiki i lecheniia bol'nykh sliunnokamennoi bolezn'iu. Granitsy neobkhodimosti ispol'zovaniia.

The authors conducted an analysis of the efficiency of the method of suandokmai for diagnosis and treatment of diseases of the salivary glands. The use of calendarscope allows to establish the absence of stone in the case of salivary colic. In rare cases it is possible to remove the stone without surgical intervention at small dimensions of the calculus. 'Price of equipment - the efficiency of diagnosis and treatment' does not allow to recommend the method in clinical practice.

[Pitfalls in diagnostic and treatment of salivary glands disorders]. / K probleme diagnostiki i lecheniia zabolevanii sliunnykh zhelez.

The paper presents a clinical case demonstrating difficulties in differential diagnosis of salivary glands disorders. The patient underwent several surgical procedures none of which was indicated. The article summarizes the reasons for diagnostic pitfalls of the case.

[Long-term clinical results of surgical treatment in patients with salivary stone disease and ducts deformation of the parotid gland]. / Otdalennye rezul'taty operativnykh vmeshatel'stv u bol'nykh sliunnokamennoi bolezn'iu i protokovymi deformatsiiami okoloushnoi sliunnoi zhelezy.

The authors with the goal of postoperative dynamic control over the results of surgical treatment of patients previously operated for salivary stone disease and various ducts deformations of the parotid salivary glands examined 16 patients with an observation period up to 8 years. It was found that recurrent acute parotitis or recurrence of stone formation was observed in 100% of cases. The authors developed methods of surgical treatment leads to long-term clinical success with no recurrence of the disease.

[Diagnosis and treatment of neurogenic dysphagia after acute ischemic stroke]. / Diagnostika i lechenie neirogennoi disfagii u bol'nykh, perenesshikh ostryi karotidnyi ishemicheskii insul't.

AIM: To determine the efficacy of post-stroke dysphagia treatment by choline alfoscerate (ChA), succinate combination (SC), and their combination with sip, larynx, and swallowing exercises. MATERIAL AND METHODS: Four groups of primary ischemic stroke (IS) patients (n=80; 62±0.2 y.o., verified by MRI), including controls, admitted to Stroke Unit 24 h after stroke in the area of RAM (29.5%), and LAM (70.5%), were studied. Basic therapy was provided according to National Stroke Treatment Recommendations, treated groups received ChA 14 mg/kg (2st gr.), SC 0.5 mg/kg (3nd gr.), combination of two compounds (3d gr.). Controls (4th gr.) received placebo. Pharmacological treatment was provided for 10 days with continuation by oral administration. Dysphagia was measured semi-quantitively by MASA scale, three scale determinants were measured on admission, on 5 and 13 days of stay in the hospital. RESULTS AND CONCLUSION: The differences were significant and observed on the 5th day of treatment. ChA mostly improved sip control, and larynx movements (38% above controls; p<0.01), while SC improved the closure of vocal cords (55% above controls; p<0.01). This may reflect the differences in synaptic control of these functions. Combined treatment was more effective than monotherapy: 15% above ChA, and 21% above SC for swallowing function (p=0.01); 33 and 22% for vocal closure, 37% (p=0.05) and 76% (p=0.01) for larynx movement, which may be due to synergism between two medications. Therefore, sip, larynx, and swallowing exercises with pharmacological support of ChA and SC ameliorated dysphagia after IS.

The 67P/Churyumov-Gerasimenko observation campaign in support of the Rosetta mission.

We present a summary of the campaign of remote observations that supported the European Space Agency's Rosetta mission. Telescopes across the globe (and in space) followed comet 67P/Churyumov-Gerasimenko from before Rosetta's arrival until nearly the end of the mission in September 2016. These provided essential data for mission planning, large-scale context information for the coma and tails beyond the spacecraft and a way to directly compare 67P with other comets. The observations revealed 67P to be a relatively 'well-behaved' comet, typical of Jupiter family comets and with activity patterns that repeat from orbit to orbit. Comparison between this large collection of telescopic observations and the in situ results from Rosetta will allow us to better understand comet coma chemistry and structure. This work is just beginning as the mission ends-in this paper, we present a summary of the ground-based observations and early results, and point to many questions that will be addressed in future studies.This article is part of the themed issue 'Cometary science after Rosetta'.